Physician profile
Stuart J Simon
NPI 1225036122
$3,318.52
in general payments reported to CMS, 2019-2025
29 companies · $664 in 2025
The $664 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $378 · 2021: $373 · 2022: $595 · 2023: $508 · 2024: $397 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,568.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $719.01 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Grifols USA, LLC | $444.57 | 2020-2025 | Prolastin-C Liquid, Xembify |
| Astrazeneca Pharmaceuticals Lp | $357.73 | 2019-2025 | Tezspire, Breztri |
| Insmed, INC. | $307.71 | 2021-2025 | Arikayce, Brinsupri |
| Jazz Pharmaceuticals INC. | $185.87 | 2020-2024 | |
| Genzyme Corporation | $131.83 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.00 | 2019-2024 | Ofev |
| Baxter Healthcare | $113.04 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Verona Pharma, INC. | $109.29 | 2025 | Ohtuvayre |
| Amgen INC. | $109.03 | 2023-2025 | Tezspire |
| Pfizer INC. | $108.54 | 2023-2025 | |
| Mylan Specialty L.P. | $107.74 | 2019-2023 | Yupelri |
| Sunovion Pharmaceuticals INC. | $55.96 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $51.58 | 2022-2023 | Dupixent |
| Philips North America LLC | $50.50 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $48.47 | 2022-2025 | Opsumit |
| 3b Medical, INC. | $46.89 | 2024 | Luna |
| Axsome Therapeutics, INC. | $39.87 | 2023 | Sunosi |
| Resmed Corp | $30.78 | 2024-2025 | |
| Electromed, INC. | $29.17 | 2019 | |
| Vapotherm INC | $26.75 | 2022 | |
| Mallinckrodt Hospital Products INC. | $18.97 | 2025 | Acthar |
| Merck Sharp & Dohme LLC | $18.51 | 2023 | Belsomra |
| Genentech USA, INC. | $17.27 | 2019 | |
| United Therapeutics Corporation | $17.27 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.37 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.49 | 2021 | |
| Gilead Sciences, INC. | $13.07 | 2021 | |
| Inogen, INC. | $2.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.